Available to mentor
Dr. Tambralli is Clinical Assistant Professor in both adult and pediatric rheumatology and sees patients across the age spectrum. He received his bachelor’s and M.D. degrees at the University of Alabama at Birmingham, and then completed a residency program in Internal Medicine and Pediatrics at the University of Rochester. He then moved to Michigan to pursue dual fellowships in adult and pediatric rheumatology at the University of Michigan. During fellowship, he was awarded the prestigious American College of Rheumatology Distinguished Fellow Award, as well as a Rheumatology Research Foundation Scientist Development Award.
Dr. Tambralli cares for children, adolescents, and adults with rheumatic diseases. He looks after all rheumatic diseases and sees patients with inflammatory arthritis, lupus, antiphospholipid syndrome, myositis, vasculitis, and autoinflammatory diseases.
Dr. Tambralli is also a part of the Jason Knight lab and participates in research on lupus and the antiphospholipid syndrome. He is working towards understanding the metabolic triggers of autoimmunity in these diseases and how to effectively harness them to develop better treatments.
-
ResidencyUniversity of Rochester Medical Center, Internal Medicine - Pediatrics
-
Fellowship in Adult and Pediatric RhematologyUniversity of Michigan–Ann Arbor, Ann Arbor
-
MDUniversity of Alabama School of Medicine, Birmingham, AL, 2014
-
BSUniversity of Alabama at Birmingham, Birmingham, AL, 2008
My research interests are to understand the role of neutrophil metabolism in the pathogenesis of the antiphospholipid syndrome and systemic lupus erythematosus to develop more targeted and less toxic therapies for our patients.
-
Tambralli A, Harbaugh A, NaveenKumar SK, Radyk MD, Rysenga CE, Sabb K, Hurley JM, Sule GJ, Yalavarthi S, Estes SK, Hoy CK, Smith T, Sarosh C, Madison JA, Schaefer JK, Sood SL, Zuo Y, Sawalha AH, Lyssiotis CA, Knight JS. J Clin Invest, 2024 Jun 13; 134 (15):Journal ArticleNeutrophil glucose flux as a therapeutic target in antiphospholipid syndrome.
DOI:10.1172/JCI169893 PMID: 38869951 -
NaveenKumar SK, Tambralli A, Fonseca BM, Yalavarthi S, Liang W, Hoy CK, Sarosh C, Rysenga CE, Ranger CH, Vance CE, Madison JA, Orsi FA, Sood SL, Schaefer JK, Zuo Y, Knight JS. Blood, 2024 Mar 21; 143 (12): 1193 - 1197.Journal ArticleLow ectonucleotidase activity and increased neutrophil-platelet aggregates in patients with antiphospholipid syndrome.
DOI:10.1182/blood.2023022097 PMID: 38237140 -
Liu C, Yalavarthi S, Tambralli A, Zeng L, Rysenga CE, Alizadeh N, Hudgins L, Liang W, NaveenKumar SK, Shi H, Shelef MA, Atkins KB, Pennathur S, Knight JS. Sci Adv, 2023 Oct 27; 9 (43): eadj1019Journal ArticleInhibition of neutrophil extracellular trap formation alleviates vascular dysfunction in type 1 diabetic mice.
DOI:10.1126/sciadv.adj1019 PMID: 37878711 -
Kmeťová K, Lonina E, Yalavarthi S, Levine JS, Hoy CK, Sarosh C, Gockman K, Morris AE, Tambralli A, Madison JA, Zuo Y, Subang R, Rauch J, Knight JS. Clin Immunol, 2023 Oct; 255: 109714Journal ArticleInteraction of the antiphospholipid syndrome autoantigen beta-2 glycoprotein I with DNA and neutrophil extracellular traps.
DOI:10.1016/j.clim.2023.109714 PMID: 37527733 -
Weiner JK, Smith T, Hoy CK, Sarosh C, Madison JA, Ambati A, Tambralli A, Peters N, Packel C, Gockman K, Zuo Y, Briceño EM, Nagaraja V, Knight JS. ACR Open Rheumatol, 2023 Jan; 5 (1): 28 - 37.Journal ArticlePredictors and Interrelationship of Patient-Reported Outcomes in Antiphospholipid Syndrome: A Cross-Sectional Study.
DOI:10.1002/acr2.11512 PMID: 36461647 -
Madison JA, Gockman K, Hoy C, Tambralli A, Zuo Y, Knight JS. Pediatr Rheumatol Online J, 2022 Feb 23; 20 (1): 17Journal ArticlePediatric antiphospholipid syndrome: clinical features and therapeutic interventions in a single center retrospective case series.
DOI:10.1186/s12969-022-00677-8 PMID: 35197077 -
Knight J, Zuo Y, Madison J, Tambralli A. 2022 Aug 1;Additional ScholarshipAPS program update newsletter
-
Knight J, Zuo Y, Madison J, Tambralli A. 2022 Aug 1;Additional ScholarshipAPS program update newsletter